Aimmune Therapeutics, Inc.
https://www.aimmune.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aimmune Therapeutics, Inc.
US FDA Envisions Advisory Committees For Allergy, Asthma Biomarkers With ‘Real Impact’
Expert panels may be used to help the FDA decide when and how a new biomarker could be leveraged for regulatory purposes. Participants at workshop on allergy and asthma biomarkers also discuss need for standardization of food allergy trials and new trial design approaches.
Novartis’s Peanut Allergy Setback Perks Up Rivals
Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.
Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Allergen Research Corporation (ARC)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice